UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Review of trials currently testing treatment and prevention of COVID-19

Clinical microbiology and infection, 2020-08, Vol.26 (8), p.988-998

2020

Volltextzugriff (PDF)

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

CPT: pharmacometrics and systems pharmacology, 2017-02, Vol.6 (2), p.87-109

2017

Volltextzugriff (PDF)

The Use of Model-Based Tumor-Size Metrics to Predict Survival

Clinical pharmacology and therapeutics, 2014-08, Vol.96 (2), p.133-135

2014

Volltextzugriff (PDF)

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

CPT: pharmacometrics and systems pharmacology, 2014-12, Vol.3 (12), p.1-4

Mentré, F

2014

Volltextzugriff (PDF)

Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling

Clinical pharmacology and therapeutics, 2012-02, Vol.91 (2), p.234-242

2012

Volltextzugriff (PDF)

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

British journal of clinical pharmacology, 2007-11, Vol.64 (5), p.603-612

2007

Volltextzugriff (PDF)

The ISoP Standards and Best Practices Committee

Clinical pharmacology and therapeutics, 2014-06, Vol.95 (6), p.581-582

2014

Volltextzugriff (PDF)

A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response

Clinical pharmacology and therapeutics, 2014-11, Vol.96 (5), p.599-608

2014

Volltextzugriff (PDF)

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

CPT: pharmacometrics and systems pharmacology, 2013-06, Vol.2 (6), p.1-2

2013

Volltextzugriff (PDF)

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

CPT: pharmacometrics and systems pharmacology, 2014-04, Vol.3 (4), p.1-9

2014

Volltextzugriff (PDF)

Pharmacokinetic and Pharmacodynamic Variability of Fluindione in Octogenarians

Clinical pharmacology and therapeutics, 2012-05, Vol.91 (5), p.777-786

2012

Volltextzugriff (PDF)

Best Practices in Population Modeling Should Always Be Evolving

CPT: pharmacometrics and systems pharmacology, 2013-07, Vol.2 (7), p.1-2

2013

Volltextzugriff (PDF)

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

CPT: pharmacometrics and systems pharmacology, 2015-06, Vol.4 (6), p.316-319

2015

Volltextzugriff (PDF)

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome

CPT: pharmacometrics and systems pharmacology, 2013-07, Vol.2 (7), p.1-9

2013

Volltextzugriff (PDF)

A Model‐Based Illustrative Exploratory Approach to Optimize the Dosing of Peg‐IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

CPT: pharmacometrics and systems pharmacology, 2015-01, Vol.4 (1), p.37-40

2015

Volltextzugriff (PDF)

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients

HIV medicine, 2004-07, Vol.5 (4), p.307-313

2004

Volltextzugriff (PDF)

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study: Table 1

The European respiratory journal, 2012-03, Vol.39 (3), p.772-775

2012

Volltextzugriff (PDF)

Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2: Clin Pharmacol Ther

Clinical pharmacology and therapeutics, 2020, Vol.108 (2)

2020

Volltextzugriff (PDF)

Cerebral uptake of mefloquine enantiomers with and without the P‐gp inhibitor elacridar (GF1210918) in mice

British journal of pharmacology, 2004-04, Vol.141 (7), p.1214-1222

2004

Volltextzugriff (PDF)

Designing an optimal experiment for Bayesian stimation: Application to the Kinetics of iodine thyroid uptake

Statistics in medicine, 1994-01, Vol.13 (2), p.185-196

1994

Volltextzugriff (PDF)

Population Pharmacokinetic Analysis of Mizolastine Using a Non Parametric Method (NPML)

Clinical pharmacology and therapeutics, 1996-02, Vol.59 (2), p.204-204

1996

Volltextzugriff (PDF)

PII-44Population pharmacokinetic models for ritonavir boosted atazanavir and tenofovir in highly pretreated HIV infected patients

Clinical pharmacology and therapeutics, 2006-02, Vol.79 (2), p.P47-P47

2006

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model

Clinical pharmacology and therapeutics, 2000-12, Vol.68 (6), p.647-657

2000

Volltextzugriff (PDF)

Influence of confounding factors on designs for dose-effect relationship estimates. Discussion

Statistics in medicine, 1995, Vol.14 (9-10), p.987-1008

1995

Volltextzugriff (PDF)

Inferring systemic exposure from a pharmacokinetic screen : model-free and model-based approaches. Discussion

Statistics in medicine, 1995, Vol.14 (9-10), p.955-970

1995

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaMiddle Aged

ThemaPhysical Sciences

KollektionWiley Online Library Journals Frontfile Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(28)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(30)
Tagungsberichte
(2)

Sprache

Englisch
(32)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Review of trials currently testing treatment and prevention of COVID-19

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

The Use of Model-Based Tumor-Size Metrics to Predict Survival

Lewis Sheiner ISoP/UCSF Lecturer Award: From Drug Use to Statistical Models and Vice Versa

Pharmacokinetic Similarity of Biologics: Analysis Using Nonlinear Mixed-Effects Modeling

Overview of model‐building strategies in population PK/PD analyses: 2002–2004 literature survey

The ISoP Standards and Best Practices Committee

A Pharmacokinetic-Viral Kinetic Model Describes the Effect of Alisporivir as Monotherapy or in Combination With Peg-IFN on Hepatitis C Virologic Response

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Powers of the Likelihood Ratio Test and the Correlation Test Using Empirical Bayes Estimates for Various Shrinkages in Population Pharmacokinetics

Pharmacokinetic and Pharmacodynamic Variability of Fluindione in Octogenarians

Best Practices in Population Modeling Should Always Be Evolving

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

Influence of a priori Information, Designs, and Undetectable Data on Individual Parameters Estimation and Prediction of Hepatitis C Treatment Outcome

A Model‐Based Illustrative Exploratory Approach to Optimize the Dosing of Peg‐IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy

Determination of indinavir and nelfinavir trough plasma concentration efficacy thresholds according to virological response in HIV‐infected patients

Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study: Table 1

Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2: Clin Pharmacol Ther

Cerebral uptake of mefloquine enantiomers with and without the P‐gp inhibitor elacridar (GF1210918) in mice

Designing an optimal experiment for Bayesian stimation: Application to the Kinetics of iodine thyroid uptake

Population Pharmacokinetic Analysis of Mizolastine Using a Non Parametric Method (NPML)

PII-44Population pharmacokinetic models for ritonavir boosted atazanavir and tenofovir in highly pretreated HIV infected patients

Pharmacokinetic and pharmacodynamic modeling of mizolastine in healthy volunteers with an indirect response model

Influence of confounding factors on designs for dose-effect relationship estimates. Discussion

Inferring systemic exposure from a pharmacokinetic screen : model-free and model-based approaches. Discussion

Aktive Filter

Suchergebnisse filtern